Latest Articles

Publication Date
Whitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial Cancers - TipRanks

Whitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial Cancers TipRanks

Published: Aug. 6, 2026, 6:39 p.m.
Sentinel Node Biopsy Gains Ground in Endometrial Cancer - Medscape

Sentinel Node Biopsy Gains Ground in Endometrial Cancer Medscape

Published: Aug. 6, 2026, 12:34 p.m.
Sentinel Node Biopsy Gains Ground in Endometrial Cancer - medscape.com

Sentinel Node Biopsy Gains Ground in Endometrial Cancer medscape.com

Published: Aug. 6, 2026, 12:34 p.m.
Study finds racial differences in ultrasound evaluation of suspected endometrial cancer - Bioengineer.org

Study finds racial differences in ultrasound evaluation of suspected endometrial cancer Bioengineer.org

Published: Aug. 4, 2026, 4:58 p.m.
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer - Clinical Oncology News

Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer Clinical Oncology News

Published: Aug. 3, 2026, 3:32 p.m.
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer - clinicaloncology.com

Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer clinicaloncology.com

Published: Aug. 3, 2026, 3:31 p.m.
Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market - openPR.com

Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market openPR.com

Published: Aug. 3, 2026, 10:50 a.m.
Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market - openpr.com

Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market openpr.com

Published: Aug. 3, 2026, 10:50 a.m.
Endometrial Cancer Market Expected to Witness Significant - openPR.com

Endometrial Cancer Market Expected to Witness Significant openPR.com

Published: Aug. 2, 2026, 5:51 p.m.
Karyopharm (KPTI) Shares Collapse 65% After Xpovio Fails Endometrial Cancer Trial Again - londoninsider.co.uk

Karyopharm (KPTI) Shares Collapse 65% After Xpovio Fails Endometrial Cancer Trial Again londoninsider.co.uk

Published: Aug. 1, 2026, 8:33 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!